drugset

drugset / Trial / NCT00424723

Pemetrexed in Patients With Advanced Neuroendocrine Tumors

NCT00424723 ↗

Phase 2 Completed 32 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Brigham and Women's Hospital · collab Massachusetts General Hospital · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out what effects (good and bad) pemetrexed has on patients with advanced neuroendocrine tumors.

Timeline

Start: 2005-12
Primary completion: 2007-01
Completion: 2010-03

Publications

Results Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH. Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8. doi: 10.1007/s00280-010-1248-6. Epub 2010 Feb 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Indications